Monograph Details
|
|
Neoplasms
> Alkylating agents
|
|
THIOTEPA |
| Manufacturer |
|
Various generic manufacturers |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Alkylating agent. |
| Generic Name |
|
Thiotepa 15mg, 30mg; per vial; pwd for IV, intravesical, or intracavitary administration after reconstitution. |
| Indications |
|
Superficial papillary carcinoma of the urinary bladder. Adenocarcinomas of the breast and ovary. Intracavitary effusion due to neoplasm of serosal cavities. |
| Children |
Not recommended.
|
| Adults |
|
Bladder cancer: avoid fluids 8–12 hrs prior to treatment. 60mg once weekly for 4 weeks; may repeat up to a total of 3 courses. Retain in bladder for 2 hours. IV administration: 0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity. |
| Contraindications |
|
Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may may be attempt a lower dose with close monitoring. |
| Precautions |
|
Monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended. |
| Interactions |
|
Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclosphosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine. |
| Adverse Reactions |
|
Myelosuppresion, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: systemic effects: rarely: chemical or hemorrhagic cystitis. |
| How Supplied |
|
Contact supplier. |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
